Further proving that mutations in the RAS-RAF-MAPK pathway often have one hit per tumor, these tumors had no other known mutations in genes often mutated in lung cancer, such as EGFR, KRAS, HER2, or PIK3CA, or BRAF. This evidence concerns the gene KRAS and lung carcinoma.